NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

• NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
  

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Sponsor

Amsterdam UMC, location VUmc

Collaborator

Celgene

Location

Netherlands

---

ClinicalTrials.gov Identifier: NCT04392037

Official Title: A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study

First Posted : May 18, 2020

Click here for details on Clinicaltrials.gov

---

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

---

Location

Europe

Netherlands